Clinical trial · Interventional
Buprenorphine for Cancer Pain
Effective Use of Buprenorphine for Long-Acting Pain Relief in Combination With Short-Acting Full Agonist Opioids for Cancer Related Pain
NCT05910190CI-TRIAL-00067875unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate patients on both buprenorphine and full agonist opioids (FAO) to assess for withdrawal symptoms. Patients will be evaluated by clinicians and using validated tools to assess for pain and withdrawal. At the same time, patients will use a CPM Rx application on their phone to track medication use.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-Related Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CPM Rx application use | Behavioral | — | UNRESOLVED |
| Use of buprenorphine with FAO > 30 OME | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Receiving buprenorphine with short acting full agonist opioid with CPM Rx app to document medication use.
- interventionNames
- Drug: Use of buprenorphine with FAO > 30 OME
- Behavioral: CPM Rx application use
Primary outcomes (2)
- measure
- Withdrawal while on Buprenorphine with Full Agonist Opioids
- timeFrame
- 3 months
- description
- Patients will be assessed on days 0 (baseline), 14, 28, 42, 56, 70, and 84 to assess for withdrawal using the validated COWS tool in conjunction with clinical assessment.
- measure
- Maximum dose of FAO with Buprenorphine
- timeFrame
- 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
1. Age greater than or equal to 18 years 2. English speaking and able to understand and sign informed consent and HIPAA consent document. 3. The patient will have pain from any cause with a pain level greater than or equal to 4 on a visual analog scale. 4. The patient will be able to complete study assessments including use of the CPM app (requires Smart Phone) 5. Patients who may become pregnant are using adequate contraceptives. 6. Patient is on the combination of buprenorphine and full agonist opioid \> 30 mg oral morphine equivalent or being started on both buprenorphine and full agonist opioid \>30 mg oral morphine equivalent at the time of enrollment
References
Publications (1)
- BACKGROUNDSchmidt-Hansen M, Taubert M, Bromham N, Hilgart JS, Arnold S. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care. 2016 Sep;6(3):292-306. doi: 10.1136/bmjspcare-2015-000939. Epub 2015 Dec 15. PMID 26669324